Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy
Over the past few years, an approach emerged that combines different receptor-specific peptide radioligands able to bind different target structures on tumor cells concomitantly or separately. The reason for the growing interest in this special field of radiopharmaceutical development is rooted in t...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 July 2020
|
| In: |
Pharmaceuticals
Year: 2020, Jahrgang: 13, Heft: 8 |
| ISSN: | 1424-8247 |
| DOI: | 10.3390/ph13080173 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/ph13080173 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1424-8247/13/8/173 
|
| Verfasserangaben: | Benedikt Judmann, Diana Braun, Björn Wängler, Ralf Schirrmacher, Gert Fricker and Carmen Wängler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1734610646 | ||
| 003 | DE-627 | ||
| 005 | 20230427033705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ph13080173 |2 doi | |
| 035 | |a (DE-627)1734610646 | ||
| 035 | |a (DE-599)KXP1734610646 | ||
| 035 | |a (OCoLC)1341368282 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Judmann, Benedikt |d 1994- |e VerfasserIn |0 (DE-588)1219163724 |0 (DE-627)173492117X |4 aut | |
| 245 | 1 | 0 | |a Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy |c Benedikt Judmann, Diana Braun, Björn Wängler, Ralf Schirrmacher, Gert Fricker and Carmen Wängler |
| 264 | 1 | |c 30 July 2020 | |
| 300 | |a 31 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.10.2020 | ||
| 520 | |a Over the past few years, an approach emerged that combines different receptor-specific peptide radioligands able to bind different target structures on tumor cells concomitantly or separately. The reason for the growing interest in this special field of radiopharmaceutical development is rooted in the fact that bispecific peptide heterodimers can exhibit a strongly increased target cell avidity and specificity compared to their corresponding monospecific counterparts by being able to bind to two different target structures that are overexpressed on the cell surface of several malignancies. This increase of avidity is most pronounced in the case of concomitant binding of both peptides to their respective targets but is also observed in cases of heterogeneously expressed receptors within a tumor entity. Furthermore, the application of a radiolabeled heterobivalent agent can solve the ubiquitous problem of limited tumor visualization sensitivity caused by differential receptor expression on different tumor lesions. In this article, the concept of heterobivalent targeting and the general advantages of using radiolabeled bispecific peptidic ligands for tumor imaging or therapy as well as the influence of molecular design and the receptors on the tumor cell surface are explained, and an overview is given of the radiolabeled heterobivalent peptides described thus far. | ||
| 650 | 4 | |a avidity | |
| 650 | 4 | |a dual targeting | |
| 650 | 4 | |a heterobivalency | |
| 650 | 4 | |a imaging | |
| 650 | 4 | |a peptides | |
| 650 | 4 | |a PET | |
| 650 | 4 | |a radiolabeling | |
| 650 | 4 | |a receptor binding | |
| 650 | 4 | |a SPECT | |
| 650 | 4 | |a therapy | |
| 700 | 1 | |a Braun, Diana |d 1996- |e VerfasserIn |0 (DE-588)1219163856 |0 (DE-627)1734921552 |4 aut | |
| 700 | 1 | |a Wängler, Björn |d 1975- |e VerfasserIn |0 (DE-588)129702218 |0 (DE-627)477593909 |0 (DE-576)297793888 |4 aut | |
| 700 | 1 | |a Schirrmacher, Ralf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fricker, Gert |d 1956- |e VerfasserIn |0 (DE-588)1042227675 |0 (DE-627)768469465 |0 (DE-576)393783464 |4 aut | |
| 700 | 1 | |a Wängler, Carmen |d 1978- |e VerfasserIn |0 (DE-588)133775593 |0 (DE-627)556368177 |0 (DE-576)30009230X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceuticals |d Basel : MDPI, 2004 |g 13(2020,8) Artikel-Nummer 173, 31 Seiten |h Online-Ressource |w (DE-627)491437528 |w (DE-600)2193542-7 |w (DE-576)281279470 |x 1424-8247 |7 nnas |a Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:8 |g extent:31 |a Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ph13080173 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/1424-8247/13/8/173 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201005 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 133775593 |a Wängler, Carmen |m 133775593:Wängler, Carmen |d 60000 |d 62900 |e 60000PW133775593 |e 62900PW133775593 |k 0/60000/ |k 1/60000/62900/ |p 6 |y j | ||
| 998 | |g 1042227675 |a Fricker, Gert |m 1042227675:Fricker, Gert |d 160000 |d 160100 |e 160000PF1042227675 |e 160100PF1042227675 |k 0/160000/ |k 1/160000/160100/ |p 5 | ||
| 998 | |g 129702218 |a Wängler, Björn |m 129702218:Wängler, Björn |d 60000 |d 62900 |e 60000PW129702218 |e 62900PW129702218 |k 0/60000/ |k 1/60000/62900/ |p 3 | ||
| 998 | |g 1219163856 |a Braun, Diana |m 1219163856:Braun, Diana |d 60000 |d 62900 |e 60000PB1219163856 |e 62900PB1219163856 |k 0/60000/ |k 1/60000/62900/ |p 2 | ||
| 998 | |g 1219163724 |a Judmann, Benedikt |m 1219163724:Judmann, Benedikt |d 60000 |d 62900 |e 60000PJ1219163724 |e 62900PJ1219163724 |k 0/60000/ |k 1/60000/62900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1734610646 |e 3766876511 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Benedikt Judmann, Diana Braun, Björn Wängler, Ralf Schirrmacher, Gert Fricker and Carmen Wängler"]},"recId":"1734610646","note":["Gesehen am 05.10.2020"],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"30 July 2020"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.3390/ph13080173"],"eki":["1734610646"]},"language":["eng"],"person":[{"role":"aut","given":"Benedikt","display":"Judmann, Benedikt","family":"Judmann"},{"role":"aut","given":"Diana","display":"Braun, Diana","family":"Braun"},{"family":"Wängler","display":"Wängler, Björn","given":"Björn","role":"aut"},{"given":"Ralf","display":"Schirrmacher, Ralf","family":"Schirrmacher","role":"aut"},{"role":"aut","given":"Gert","display":"Fricker, Gert","family":"Fricker"},{"role":"aut","given":"Carmen","family":"Wängler","display":"Wängler, Carmen"}],"title":[{"title_sort":"Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy","title":"Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy"}],"physDesc":[{"extent":"31 S."}],"relHost":[{"part":{"volume":"13","year":"2020","extent":"31","text":"13(2020,8) Artikel-Nummer 173, 31 Seiten","issue":"8"},"title":[{"title":"Pharmaceuticals","title_sort":"Pharmaceuticals"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"MDPI","dateIssuedKey":"2004","dateIssuedDisp":"2004-","publisherPlace":"Basel"}],"language":["eng"],"id":{"zdb":["2193542-7"],"issn":["1424-8247"],"eki":["491437528"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 05.09.2011"],"pubHistory":["1.2004 -"],"recId":"491437528","name":{"displayForm":["Molecular Diversity Preservation International"]},"disp":"Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapyPharmaceuticals"}]} | ||
| SRT | |a JUDMANNBENCURRENTSTA3020 | ||